Portal de Periódicos da CAPES

The role of IgE in allergen‐induced inflammation and the potential for intervention with a humanized monoclonal anti‐IgE antibody

2001; Wiley; Volume: 31; Issue: 9 Linguagem: Inglês

10.1046/j.1365-2222.2001.01162.x

1365-2222

Syed Hasan Arshad, Stephen T. Holgate,

Food Allergy and Anaphylaxis Research

Clinical & Experimental AllergyVolume 31, Issue 9 p. 1344-1351 The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody S. H. Arshad, S. H. Arshad Division of Respiratory Cell and Molecular Biology (RCMB), School of Medicine, University of Southampton, Southampton, UKSearch for more papers by this authorS. Holgate, S. Holgate Division of Respiratory Cell and Molecular Biology (RCMB), School of Medicine, University of Southampton, Southampton, UKSearch for more papers by this author S. H. Arshad, S. H. Arshad Division of Respiratory Cell and Molecular Biology (RCMB), School of Medicine, University of Southampton, Southampton, UKSearch for more papers by this authorS. Holgate, S. Holgate Division of Respiratory Cell and Molecular Biology (RCMB), School of Medicine, University of Southampton, Southampton, UKSearch for more papers by this author First published: 20 December 2001 https://doi.org/10.1046/j.1365-2222.2001.01162.xCitations: 21 S. H. Arshad, Department of Medical Specialties, Level D, Centre Block, Southampton General Hospital, Tremona Road, Shirley, Southampton SO16 6YD, UK. E-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Holgate ST, Robinson C, Church MK. Mediators of immediate hypersensitivity. In: E Middleston, CE Reed, EF Regis et al., eds. Allergy Principles and Practice 4th edn. St Louis, Missouri: Mosby, 1993: 267–301. 2 O'Byrne PM, Dolovich J, Hargreave FE. Late asthmatic responses. Am Rev Respir Dis 1987; 136: 740–51. 3 Cockcroft DW & Murdock KY. Changes in bronchial responsiveness to histamine at intervals after allergen challenge. Thorax 1987; 42: 302–8. 4 Oddera S, Silvestri M, Penna R et al. Airway eosinophilic inflammation and bronchial hyperresponsiveness after allergen inhalation challenge in asthma. Lung 1998; 176: 237–47. 5 Brusasco V, Crimi E, Gianiorio P, Lantero S, Rossi GA. Allergen-induced increase in airway responsiveness and inflammation in mild asthma. J Appl Physiol 1990; 69: 2209–14. 6 Djukanovic R, Feather I, Gratziou C et al. Effect of natural allergen exposure during the grass pollen season on airways inflammatory cells and asthma symptoms. Thorax 1996; 51: 575–81. 7 Bahna S. A 21-year salute to IgE. Ann Allergy 1989; 62: 471–8. 8 Ishizaka K & Ishizaka T. Biological function of gamma E antibodies and mechanisms of reaginic hypersensitivity. Clin Exp Immunol 1970; 6: 25–42. 9 Metzger H. The receptor with high affinity for IgE. Immunol Rev 1992; 125: 37–48. 10 Arshad SH. Bronchial allergen challenge: a model for chronic allergic asthma? Clin Exp Allergy 2000; 30: 12–5.DOI: 10.1046/j.1365-2222.2000.00734.x 11 Togias A. Unique mechanistic features of allergic rhinitis. J Allergy Clin Immunol 2000; 105: S599–604. 12 Haugaard L, Iversen M, Dahl R. Predictors of early- and late-phase reactions to bronchial allergen challenge. Allergy 1997; 52: 999–1004. 13 Cockcroft DW, Ruffin RE, Frith PA et al. Determinants of allergen-induced asthma: dose of allergen, circulating IgE antibody concentration, and bronchial responsiveness to inhaled histamine. Am Rev Respir Dis 1979; 120: 1053–8. 14 Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987; 135: 264–7. 15 Lemanske RF Jr & Kaliner MA. Late phase allergic reactions. In: E Middleston, CE Reed, EF Regis et al., eds. Allergy Principles and Practice 4th edn. St Louis, Missouri: Mosby, 1993: 320–61. 16 Durham SR, Lee TH, Cromwell O et al. Immunologic studies in allergen-induced late-phase asthmatic reactions. J Allergy Clin Immunol 1984; 74: 49–60. 17 Van Der Veen MJ, Van Neerven RJ, De Jong EC et al. The late asthmatic response is associated with baseline allergen- specific proliferative responsiveness of peripheral T lymphocytes in vitro and serum interleukin-5. Clin Exp Allergy 1999; 29: 217–27.DOI: 10.1046/j.1365-2222.1999.00466.x 18 Aalbers R, Kauffman HF, Vrugt B et al. Bronchial lavage and bronchoalveolar lavage in allergen-induced single early and dual asthmatic responders. Am Rev Respir Dis 1993; 147: 76–81. 19 Holt PG, Macaubas C, Stumbles PA, Sly PD. The role of allergy in the development of asthma. Nature 1999; 402: B12–7. 20 Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax 1999; 54: 268–72. 21 Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. New Engl J Med 1989; 320: 271–7. 22 Ishizaka T, Ishizaka K, Conrad DH, Froese A. A new concept of triggering mechanisms of IgE-mediated histamine release. J Allergy Clin Immunol 1978; 61: 320–30. 23 Sears MR, Burrows B, Flannery EM et al. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 1991; 325: 1067–71. 24 Platts-Mills TA. Mechanisms of bronchial reactivity: the role of immunoglobulin E. Am Rev Respir Dis 1992; 145: S44–7. 25 Sunyer J, Anto JM, Sabria J et al. Relationship between serum IgE and airway responsiveness in adults with asthma. J Allergy Clin Immunol 1995; 95: 699–706. 26 Tschopp JM, Sistek D, Schindler C et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests and Phadiatop). Results from 8329 randomized adults from the SAPALDIA Study. Swiss Study on Air Pollution and Lung Diseases in Adults. Allergy 1998; 53: 608–13. 27 Scrivener S & Britton J. Immunoglobulin E and allergic disease in Africa. Clin Exp Allergy 2000; 30: 304–7.DOI: 10.1046/j.1365-2222.2000.00790.x 28 Palmer LJ, Burton PR, Faux JA et al. Independent inheritance of serum immunoglobulin E concentrations and airway responsiveness. Am J Respir Crit Care Med 2000; 161: 1836–43. 29 Watson N, Bodtke K, Coleman RA et al. Role of IgE in hyperresponsiveness induced by passive sensitization of human airways. Am J Respir Crit Care Med 1997; 155: 839–44. 30 Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur Respir J 2000; 16: 609–14.DOI: 10.1034/j.1399-3003.2000.16d07.x 31 Bettiol J, Bartsch P, Louis R et al. Cytokine production from peripheral whole blood in atopic and nonatopic asthmatics: relationship with blood and sputum eosinophilia and serum IgE levels. Allergy 2000; 55: 1134–41.DOI: 10.1034/j.1398-9995.2000.00711.x 32 Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A system review and meta-analysis. Arch Intern Med 1999; 159: 941–55. 33 Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999; 340: 197–206. 34 Mannino DM, Homa DM, Pertowski CA et al. Surveillance for asthma — United States, 1960–95. Mor Mortal Wkly Rep CDC Surveill Summ 1998; 47: 1–27. 35 Jonasson G, Lodrup Carlsen KC, Leegaard J et al. Trends in hospital admissions for childhood asthma in Oslo, Norway. 1980–95. Allergy 2000; 55: 232–9.DOI: 10.1034/j.1398-9995.2000.00387.x 36 Malmstrom K, Korhonen K, Kaila M et al. Acute childhood asthma in Finland: a retrospective review of hospital admissions from 1976 to 1995. Pediatr Allergy Immunol 2000; 11: 236–40.DOI: 10.1034/j.1399-3038.2000.00090.x 37 Adkinson NF Jr, Eggleston PA, Eney D et al. A controlled trial of immunotherapy for asthma in allergic children. N Engl J Med 1997; 336: 324–31. 38 Frew AJ. Injection immunotherapy. British Society for Allergy and Clinical Immunology Working Party. BMJ 1993; 307: 919–23. 39 Haile S, Lefort J, Eum SY et al. Suppression of immediate and late responses to antigen by a non-anaphylactogenic anti-IgE antibody in a murine model of asthma. Eur Respir J 1999; 13: 961–9.DOI: 10.1034/j.1399-3003.1999.13e06.x 40 Presta LG, Lahr SJ, Shields RL et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623–32. 41 Hakimi J, Chizzonite R, Luke DR et al. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol 1991; 147: 1352–9. 42 Shawler DL, Bartholomew RM, Smith LM, Dillman RO. Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985; 135: 1530–5. 43 Junghans RP, Waldmann TA, Landolfi NF et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 1990; 50: 1495–502. 44 Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323–7. 45 MacGlashan DW Jr, Bochner BS, Adelman DC et al. Down-regulation of Fc (epsilon) RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997; 158: 1438–45. 46 Scheoenoff M, Lin Y, Froehlich J, Fick R, Bates D. A pharmacodynamic model describing free IgE concentrations following administration of a recombinant humanized monoclonal anti-IgE antibody in humans. Pharm Res 1995; 12 (Suppl.): S411. 47 Bisberg D, Froehlich J, Schoenhoff M, Mendelson J. Multiple administrations of the anti-IgE recombinant humanized monoclonal antibody E25 (rhuMAb-E25) reduces free IgE levels in a dose dependent manner in adolescents and children with moderate to severe allergic asthma. J Clin Pharmacol 1996; 36: 859. 48 Fahy JV, Cockcroft DW, Boulet LP et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 1999; 160: 1023–7. 49 Burr ML, Butland BK, King S, Vaughan-Williams E. Changes in asthma prevalence: two surveys 15 years apart. Arch Dis Child 1989; 64: 1452–6. 50 Peat JK, Van Den Berg RH, Green WF et al. Changing prevalence of asthma in Australian children. BMJ 1994; 308: 1591–6. 51 Shapiro GG, Wighton TG, Chinn T et al. House dust mite avoidance for children with asthma in homes of low- income families. J Allergy Clin Immunol 1999; 103: 1069–74. 52 Carswell F, Birmingham K, Oliver J, Crewes A, Weeks J. The respiratory effects of reduction of mite allergen in the bedrooms of asthmatic children – a double-blind controlled trial. Clin Exp Allergy 1996; 26: 386–96. 53 Boulet LP, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835–40. 54 Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828–34. 55 Demoly P & Bousquet J. Anti-IgE therapy for asthma. Am J Respir Crit Care Med 1997; 155: 1825–7. 56 Milgrom H, Fick RB Jr, Su JQ et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966–73. 57 Busse W, Corren J, Lanier B et al. rhuMAb-E25 (E25): a novel therapy for the treatment of allergic asthma (AA). J Allergy Clin Immunol 2000; 105:(6, Pt 1): 5. 58 Milgrom H, Nayak A, Berger W et al. The efficacy and safety of rhuMAb-E25 (E25) in children with allergic asthma (AA). J Allergy Clin Immunol 2000; 105:(6, Pt 1): 4. 59 Togias A, Corren J, Shapiro G et al. Anti-IgE treatment reduces skin test (ST) reactivity. J Allergy Clin Immunol 1998; 101: S171. 60 Casale T, Condemi JJ, Miller SD et al. rhuMAb-E25 in the treatment of seasonal allergic rhinitis (SAR). Ann Allergy Asthma Immunol 1999; 82(1): 75. 61 Casale TB, Racine A, Sallas W et al. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 104: S357. 62 Nayak A, LaForce C, Rowe M et al. rhuMAb-E25 improves quality of life in patients with seasonal allergic rhinitis (SAR). J Allergy Clin Immunol 1999; 103: S49. 63 Adelroth E, Rak S, Haahtela T et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253–9. 64 Slater JE. Latex allergy. J Allergy Clin Immunol 1994; 94: 139–49. 65 Franklin W & Pandolfo J. Latex as a food allergen. N Engl J Med 1999; 341: 1858. 66 Sampson HA. Epidemiology of food allergy. Pediatr Allergy Immunol 1996; 7: 42–50. 67 Burks W, Bannon GA, Sicherer S, Sampson HA. Peanut-induced anaphylactic reactions. Int Arch Allergy Immunol 1999; 119: 165–72. 68 Coyle AJ, Wagner K, Bertrand C et al. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: inhibition by a non-anaphylactogenic anti-IgE antibody. J Exp Med 1996; 183: 1303–10. Citing Literature Volume31, Issue9September 2001Pages 1344-1351 ReferencesRelatedInformation